Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
Type
Guidance (295)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 81 to 90 of 326
Guidance and quality standards awaiting development
Title
Type
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]
Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]
Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146
Technology appraisal guidance
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer ID6490
Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]
Technology appraisal guidance
Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]
Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Technology appraisal guidance
Previous page
1
…
7
8
Current page
9
10
11
…
33
Page
9
of
33
Next page
Results per page
10
25
50
All
Back to top